Alexandros Georgiou

7PUBLICATIONS
22CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Nanotoxicology, health and safetyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jan 10, 2026
Outcomes Following Radiotherapy for Oligoprogressive NSCLC on Immune Checkpoint Inhibitors: A Real-World, Multinational Experience.

Umair Mahmood, Eleni Josephides, Nicholas Coupe

|Nov 26, 2025
A Retrospective Analysis of Endovascular Stent Insertion for Malignant Superior Vena Cava Obstruction, Focusing on Anticoagulation Practices.

Joshua Walker, Amsajini Ravinthiranathan, Athanasios Diamantopoulos

|Sep 13, 2025
Predictors and Outcomes of Non-Small Cell Lung Carcinoma Patients Following Severe Immune Checkpoint Inhibitor Toxicity: A Real-World UK Multi-Centre Study.

Umair Mahmood, Eleni Josephides, Meenali Chitnis

|Apr 05, 2025
PD-L1 imaging with [99mTc]NM-01 SPECT/CT is associated with metabolic response to pembrolizumab with/without chemotherapy in advanced lung cancer.

Daniel Johnathan Hughes, Gitasha Chand, Jessica Johnson

|Sep 14, 2024
Real-World Analysis of Survival and Treatment Efficacy in Stage IIIA-N2 Non-Small Cell Lung Cancer.

Eleni Josephides, Roberta Dunn, Annie-Rose Henry

|Dec 23, 2022
Non-Small Cell Lung Cancer (NSCLC) in Young Adults, Age < 50, Is Associated with Late Stage at Presentation and a Very Poor Prognosis in Patients That Do Not Have a Targeted Therapy Option: A Real-World Study

Daniel Johnathan Hughes, Matthaios Kapiris, Andreja Podvez Nevajda

Pageof 2

Frequent Collaborators

3 joint publications

Spyridon Gennatas

3 joint publications

Daniel Smith

2 joint publications

Daniel Johnathan Hughes

1 joint publications

Georgios Vlachogiannis